Triptorelin 0.1 mg as a Luteal Phase Support in Antagonist Intracytoplasmic Sperm Injection Cycles

Transvaginal progesterone is used to aid throughout the luteal phase. Administering a dose of gonadotrophin-releasing-hormone analogues (GnRHa) six days following OPU in GnRH antagonist cycles might cause rise in pituitary gonadotropins (luteinizing hormone (LH) and follicle-stimulating hormone (FSH)), leading to rise in steroid synthesis (estradiol (E2) and progesterone (P)) by the corpora lutea (CL). This work aimed to contrast the effect of lipopolysaccharides (LPS) with adding GnRHa to progesterone P, at day six after ovum pickup versus P alone, on the clinical pregnancy rate.

This open labeled randomized controlled trial study was carried out at women health hospital (WHH), Assiut University on 150 women with antagonist controlled ovarian hyperstimulation protocol (COH). Individuals had been categorized into two groups: Study group: include women who obtained 0.1 mg of GnRH agonist "triptorelin" at day 6 after OPU in addition to (P) since day of oocyte pickup (OPU) compared with the control group: administration of P only since (OPU) as LP support.

Women who received GnRHa 0.1 mg & P as LPS were reported significant higher progesterone level, beta human chorionic gonadotropins (BHCG) level, fetal pulsation, implantation rate, clinical pregnancy rate, biochemical pregnancy rate, ongoing pregnancy and live birth rates contrasted to control group (P < 0.05).

Adding GnRHa to P as LPS is associated with significant higher progesterone level at day 7 after OPU BHCG day 14 of embryo transfer, clinical pregnancy rate, biochemical pregnancy rate, implantation rate, ongoing pregnancy rate, and live birth rate.